Which cancer drugs go off patent, and when?
20 blockbuster cancer drugs with about $126.0B in 2025 worldwide sales lose US exclusivity between 2025 and 2037, led by Keytruda (Merck, $31.7B). 3 lose it in 2025 or 2026; the biggest single year is 2028, with $49.1B.
2025 worldwide sales of each drug, placed in the year its first US generic or biosimilar can launch. Select a year for every drug going off patent that year.
| Drug | Company | US LOE | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Xgeva | Amgen | 2025 | $2.1B | Biosimilars launched | Copies on the US market | – |
| Perjeta | Roche | 2026 | ≈$3.6B | Company guidance | Approved, waiting to launch | – |
| Pomalyst | Bristol Myers Squibb | 2026 | $2.7B | Generics launched | Copies on the US market | 2027 · −60% |
| Xtandi | Astellas / Pfizer | 2027 | ≈$6.0B | Patent-expiry estimate | Approved, waiting to launch | 2027 · −48% |
| Ibrance | Pfizer | 2027 | $4.1B | Patent-expiry estimate | Filed with the FDA | 2027 · −50% |
| Lynparza | AstraZeneca / Merck | 2027 | $3.3B | Company guidance | Tentatively approved | – |
| Keytruda | Merck | 2028 | $31.7B | Company guidance | In clinical trials | – |
| Opdivo | Bristol Myers Squibb | 2028 | $10.1B | Company guidance | Filed with the FDA | – |
| Tecentriq | Roche | 2028 | ≈$4.3B | Patent-expiry estimate | No US filing found | – |
| Jakafi | Incyte | 2028 | $3.1B | Company guidance | Filed with the FDA | – |
| Darzalex | Johnson & Johnson | 2029 | $14.3B | Patent-expiry estimate | In clinical trials | – |
| Imfinzi | AstraZeneca | 2031 | $6.1B | Company guidance | Early development | – |
| Verzenio | Eli Lilly | 2031 | $5.7B | Company guidance | No US filing found | 2028 · pending |
| Kisqali | Novartis | 2031 | $4.8B | Company guidance | No US filing found | 2028 · pending |
| Cabometyx | Exelixis | 2031 | $2.1B | Settlement / court date | Approved, waiting to launch | – |
| Tagrisso | AstraZeneca | 2032 | $7.3B | Patent-expiry estimate | No US filing found | – |
| Imbruvica | AbbVie / Johnson & Johnson | 2032 | $4.9B | Settlement / court date | Approved, waiting to launch | 2026 · −38% |
| Calquence | AstraZeneca | 2032 | $3.5B | Patent-expiry estimate | Filed with the FDA | 2027 · −40% |
| Venclexta | AbbVie | 2032 | $2.8B | Patent-expiry estimate | Filed with the FDA | – |
| Erleada | Johnson & Johnson | 2033 | $3.6B | Patent-expiry estimate | Filed with the FDA | 2028 · pending |
Sorted by the year US exclusivity ends. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Merck | Lynparza and Keytruda | $33.1B | 51% |
| Johnson & Johnson | Darzalex, Imbruvica and Erleada | $20.7B | 22% |
| AstraZeneca | Lynparza, Imfinzi, Tagrisso and Calquence | $20.2B | 34% |
| Bristol Myers Squibb | Pomalyst and Opdivo | $12.8B | 27% |
| Roche | Perjeta and Tecentriq | ≈$7.9B | 11% |
| Pfizer | Xtandi and Ibrance | $6.3B | 10% |
| Astellas | Xtandi | ≈$6.0B | 45% |
| Eli Lilly | Verzenio | $5.7B | 8.8% |
| AbbVie | Imbruvica and Venclexta | $5.7B | 9.2% |
| Novartis | Kisqali | $4.8B | 8.8% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Pomalyst (2027, −60%), Xtandi (2027, −48%), Ibrance (2027, −50%), Verzenio (2028, price pending), Kisqali (2028, price pending), Imbruvica (2026, −38%), Calquence (2027, −40%) and Erleada (2028, price pending) were selected for Medicare price negotiation. See every negotiated Medicare price →